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Abstract:
Background: Multiple drug hypersensitivity syndrome (MDH) is used to describe persons with a 
drug hypersensitivity reaction (DHR) to at least two chemically unrelated drugs, confirmed by skin 
test or in vitro assay.
Methods: Medical records of 25 patients with MDH, tested and confirmed at our allergy division 
were retrospectively evaluated in terms of clinical course, involved drugs, daily drug dose, latency 
periods, test results of skin test and cellular assays and tolerated drugs in subsequent 
pharmacological treatments.
Results: MDH almost exclusively appeared as a delayed, often severe DHR and started in 14/25 
with a drug reaction with eosinophilia and systemic symptoms (DRESS). Penicillins (13/25, 
52.0%) and cephalosporins (6/25, 24.0%), typical high dose drugs, were most often identified as 
elicitors of MDH, especially at the first DHR, followed by aromatic antiepileptics (7/25, 28.0%), 
vancomycin (4/25, 16.0%) and antibiotic sulfonamides (4/25, 16.0%). Cephalosporins, 
clindamycine and radio contrast media (RCM) were mainly involved in subsequent DHR. The 
median daily drug dose of all drug trigger was 1875.0 mg (662.5; 2100.0) at the first DHR and 
600.0 mg (300.0; 1300.0) at subsequent DHR, p=0.0420.
Conclusion. High dose drugs, especially betalactam antibiotics, RCM and clindamycin are 
common elicitors of subsequent DHR in patients with MDH. Macrolides, quinolones, doxycycline, 
non-aromatic antiepileptics and paracetamol were often tolerated. As the same drugs elicited 
both flare-up reactions and real DHR, drug induced flare-up reactions may be precursors of a 
possible second DHR and MDH. The administration of highly dosed drugs should be avoided in 
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Introduction
Multiple drug hypersensitivity syndrome (MDH) was originally described in case reports by 
Sullivan et al. [1] and was based on clinical criteria and some skin tests. This syndrome was 
“revived” by analyzing T cell reactivity of patients with drug hypersensitivity [2]: it was noted that 
some patients with a T cell reaction to drugs (exanthema, DRESS) had a strong reactivity to more 
than one drug in vitro (lymphocyte transformation test (LTT)) and in vivo (mainly patch tests (PT)) 
[2]. These observations were summarized in case series [2, 3, 4, 5, 6, 7, 8] and defined as a drug 
hypersensitivity reaction (DHR) to at least 2 chemically and pharmacologically unrelated drugs [2, 
7]. Three subforms of MDH were described according to the sequence of symptoms onset: (1) 
the simultaneous form, based on the appearance of symptoms to two drugs or more 
simultaneously (in the case of combination therapy for instance), (2) the sequential form in which 
subsequent reactions occur during the acute stage, and (3) the distant form when reactions occur 
to drugs given months to years apart [2, 7]. To distinguish this syndrome from other drug 
reactions, it was recommended to prove the double or triple reactivity by skin or in vitro tests to 
two or more drugs [2, 7]. The proof of an immune mediated mechanism allows to exclude any 
drug intolerance or pseudoallergic reactions, where e.g. various chemically distinct non-steroidal 
anti-inflammatory drugs (NSAID) may be responsible for repeated reactions as well [9]. 
The pathophysiology of MDH is under investigation. In the initial descriptions by Sullivan [1], no 
distinction of immediate and delayed reactions were made. In the later more detailed studies on 
MDH, the initial clinical symptoms and drug specific T cell reactivity in vitro and in vivo suggested 
that this syndrome starts with a strong T cell reactivity [10]. A step forward in analyzing the 
mechanism of MDH was the study of Daubner B et al. [11]. T cell reactivity of seven MDH 
patients has been compared with 6 mono-allergic patients with maculopapular exanthema (MPE). 
They could show that the multiple reactivity was not due to cross-reactivity. No deficiency of T reg 
cells in reactions to drugs or the control antigen tetanus toxoid could be observed in MDH or in 
the control MPE patients [11]. A puzzling finding was the observation that patients with a prior 
MDH carried, months to years after the acute symptoms, still a population of activated T cells in 
the circulation, although no infection and no clinical sign of auto-immune disease were evident.  
These cells were CD4+, CD25dim, CD38+, PD1+ and could be found only in MDH patients and 
not in mono-allergic patients with prior MPE [11]. Interestingly, the same activated T cells were 
also described in patients with chronic viral disease or graft versus host disease [12]. Based on 
new studies on immune stimulations of T cells by drugs, which emphasized the similarity of drug 









This article is protected by copyright. All rights reserved
study of Daubner et al. [11] it was hypothesized that MDH represents a kind of chronic graft 
versus host disease like condition, developing from an acute DHR, which ends up in a chronic 
stimulation.
The aim of this study was to highlight certain clinical hallmarks of MDH and to elaborate clinical 
recommendations how to diagnose and treat patients with MDH or patients at risk for developing 
MDH. Only patients with proven immune mediated mechanism of MDH were included. We 
focused on the eliciting drugs, especially on drugs responsible for subsequent reactions, on the 
timing and dose of the drugs and on the role of comorbidities.  We also provide a list of drugs, 
which were tolerated in subsequent pharmacological treatments. Together these clinical findings 
result in recommendations how one could manage patients with MDH or at risk for MDH.
Methods
Study design
Patients with a diagnosis of MDH, tested and confirmed at our allergy division were 
retrospectively identified in February 2019 with a search tool from the hospital record database. 
Search terms included "multiple drug hypersensitivity", "MDH" and we screened for patients with 
sensitization to two or more drugs. All patients gave informed consent to the evaluation of their 
drug allergy history. The study was approved of the local ethics committee (Kantonale 
Ethikkommission Bern). The project was conducted in accordance with the protocol, the 
Declaration of Helsinki, the principles of Good Clinical Practice and locally relevant regulations. 
Study population
Patients with a visit at our allergy division between January 2011 and December 2018 were 
included in the study. We defined MDH as a immunologically mediated DHR to two or more 
unrelated drugs and defined therefore the following inclusion criteria: one or more clinically well 
documented DHR with detection of at least 2 or more structurally different drug triggers either by 
skin or in vitro tests (table 1). Skin tests were performed and read according to the EAACI/ENDA 
guidelines [14]. Exclusion criteria were reactions with subjective symptoms (only pruritus, 
discomfort, pain etc.), drug reactions suggestive for pharmacologic side effects, reactions to 
pharmacologically related drugs, possible cross reactivity between causative drugs, doubtful test 
results (irritative, repeated negative tests), and patients with chronic spontaneous urticaria or 
urticarial dermographism. Patients with DHR diagnosed by drug provocation test (DPT) only were 
excluded too, as DPT cannot distinguish between immunological and non-immunological DHR.
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We evaluated the medical records of each MDH case for numbers and the type of DHR (DRESS, 
MPE, acute generalized exanthematous pustulosis (AGEP), Stevens Johnson syndrome (SJS), 
toxic epidermal necrolysis (TEN), symmetrical drug related intertriginous and flexural exanthema 
(SDRIFE), anaphylaxis (ANA) etc.). It was determined whether a patient developed only a single 
DHR with sensitization to combination therapies or sequentially given drugs within the same DHR 
episode or MDH with two or more DHR. The initial manifestation of MDH was defined as first 
DHR, all following DHR defined as subsequent DHR. Drug-induced flare-up reactions were 
distinguished from DHR and defined as a rebound of clinical symptoms such as exanthema, 
elevation of liver enzymes and eosinophilia to a new given drug without eliciting sensitization. 
Drug induced flare-ups occur usually during or after an acute DHR-phase [15, 16], resulting in the 
withdrawal of this drug. According to the skin and the in vitro tests (lymphocyte transformation 
test), drug triggers for each DHR were recorded. In addition, age, gender, latency period (start of 
therapy until symptoms occur), daily drug dose and trigger of drug induced flare-up reactions 
were extracted from the medical records. Any comorbidity present at the first DHR was 
investigated. 
For each case we evaluated which new drugs were used and whether they were well tolerated 
(no subsequent DHR, no drug induced flare-up reaction). We focused on antibiotics, 
antiepileptics, analgesics, contrast agents and proton pump inhibitors. We analyzed the 
relationship of patients who were exposed to a particular drug after the first DHR and how many 
of them tolerated it (tolerated/exposed). We classified drugs that were tolerated in 75% of cases 
administered as mostly tolerable.
Statistical analysis
Results were evaluated by descriptive statistics. Analysis were performed using Graphpad Prism 
8 (GraphPad Software, Inc, La Jolla, Calif). Categorical variables (e.g., gender, type of 
hypersensitivity reaction, culprit drug, etc.) are expressed in percentage. Continuous variables (e. 
g. age, drug dose, latency period etc.) are reported as median and interquartile ranges. The Man-




Out of 39 patients screened, we analyzed the data of 25 cases (14 patients were excluded, 7 not 
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declined to participate). 15/25 (60.0%) patients were female, the median age at the first DHR was 
50 years (range 5-73). Only one child was identified with MDH (5 years old). An IgE mediated 
mechanism was found in one patient who had a combination of an immediate and delayed type 
DHR (table 4, patient number 8). Most patients developed a severe delayed DHR as first DHR: 
14/25 (56.0%) fulfilled the criteria of a DRESS (Regiscar score of 5 or more) [17], 5/25 patients 
(20.0%) had a generalized MPE (of which 3 with fever and facial swelling), two patients each 
developed a SJS/TEN (8.0%) and AGEP (8.0%), one patient a bullous exanthema (table 2). 
15/25 had 2 or more DHR, of which 11 subjects developed a different manifestation of DHR. The 
most frequent subsequent DHR was an MPE (11/15, 73.3%), followed by AGEP (3/15, 20.0%), 
DRESS (2/15, 13.3%) and SDRIFE (1/15, 6.7%). Epilepsy was the most frequent concomitant 
diseases (8/25, 32.0%), followed by renal insufficiency (7/25, 28.0%) and autoimmune disorders 
(7/25, 28.0%).  We found most frequently a distant form of MDH (11/25, 44%), followed by 
sequential (6/25, 24%) and simultaneous (5/25, 20%), 3 patients had an overlap (3/25, 12%).
Trigger of MDH and drug induced flare-up reactions
Findings of all MDH trigger are summarized in figure 1. Betalactam antibiotics, especially 
penicillins (13/25, 52.0%) were most often identified as trigger, followed by cephalosporins (6/25, 
24.0%). Penicillins were primarily involved in the first DHR (12/25), aromatic antiepileptics (7/25, 
28.0%) caused only first DHR. On the other hand vancomycin (4/25, 16.0%) and sulfonamide 
antibiotics (4/25, 16.0%) were involved in both first and subsequent DHR. Clindamycin (4/25, 
16.0%), non-aromatic antiepileptics (2/25, 8.0%) and radio contrast agents (4/25, 16.0%) almost 
never caused a first DHR. Two patients had an immune mediated DHR to a non steroidal anti-
inflammatory drug (metamizole, diclofenac).
Drug-induced flare-up reactions occurred in 13 patients (13/25, 52.0%), of which 8 had a DRESS 
as a first DHR. Cephalosporins (5/25, 20.0%) were at the top of the ranking as trigger for drug 
induced flare-up reactions, followed by clindamycin and metamizole (each 2/25, 8.0%).
Tolerated drugs
In 22 out of 25 patients we had information on the medication administered after the first DHR 
(table 3). Although betalactam antibiotics have been often involved in first DHR, they seem to be 
tolerated later at least partially: 4 out of 6 tolerated penicillins and 4 out of 12 tolerated 
cephalosporins. The classic DRESS triggers vancomycin (0/2), antibiotic sulfonamides (0/2) and 
aromatic antiepileptics (0/1) were never tolerated. One patient (table 4, number 8) tolerated 
lamotrigine if administered below a daily dose of 100mg. Clindamycin was often used, but never 
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tolerated antibiotics. Regarding antiepileptic drugs, non-aromatic antiepileptic drugs (8/10) 
(especially valproate, levetiracetam and topiramat) and benzodiazepines (4/4) usually seem to be 
well tolerated. Paracetamol (11/12) and opiates (9/9) were successfully used as analgesic drugs, 
ibuprofen was tolerated in 4 patients (4/4). Metamizole seemed to be tolerated only partially (4/7).
The role of drug dose
Drug dose was evaluated in patients with delayed DHR (n=24). At the first DHR the daily dose of 
all drug trigger exceeded 1000mg (median 1875.0 mg (662.5; 2100.0)). Interestingly, the daily 
drug dose in subsequent DHR was significantly lower than at the first DHR, (600.0 mg (300.0; 
1300.0)), p=0.0420. (figure 2a).
Latency period
The median latency period for the first DHR was 19.0 days (19.0 (9.0; 28.0)), and 3 days for 
subsequent DHR (3.0 (2.0; 7.0), p<0.0001 (figure 2b). The shortest latency time overall (table 4, 
patient number 12) was 2 hours in a subsequent DHR. Although resembling anaphylaxis, the 
mechanism was T cell mediated. 
The median time interval between the first and the second DHR was 26 (6.0; 71.0) months.
Discussion
MDH is a chronic condition developing from an acute and severe T cell mediated DHR [11]. Why 
only some patients with DRESS or severe MPE develop symptoms of MDH, and others not, is 
unclear. The aim of this study was to describe the clinical aspects of patients with MDH, namely 
of the first and subsequent DHR of MDH, the type of drugs and the role of dosing. 
1. Analysis of the first DHR
As previously described in MDH case series [2, 3, 4, 5, 6, 7, 8], classical DRESS triggers, 
especially antiepileptics, sulfonamides and vancomycin were often the responsible drugs for the 
first DHR. This observation is not different from severe DHR not linked to MDH [18]. However, 
betalactam antibiotics, in particular penicillins and cephalosporins were often responsible for first 
DHR with more than half of our MDH cohort reacting 
2. Analysis of subsequent DHR
Of particular interest was the analysis of the subsequent DHR. The following differences 
compared to the first DHR were found: 
a) Drugs causing subsequent DHR were different from the ones causing first DHR. This may be 
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appearing repeatedly in subsequent DHR but rarely found as elicitors of a first DHR, are 1. 
clindamycin, which is a rare cause of DHR [19], but was responsible in 3 patients for subsequent 
DHR and in 2 for a flare up reaction, 2. the analgesic drug metamizole was found in subsequent 
DHR and flare-up reactions, mainly with MPE and 3. radio contrast media (RCM) were involved in 
3 subsequent DHR. T-cell reactions to RCM in the normal population is usually mild [20]. Based 
on our study, it seems that triggering DHR enhances the subsequent reactivity to RCM (seen in 
3/25).
b) The dose of drug trigger in subsequent DHR was substantially lower than in the first DHR. It is 
striking that most drug trigger, especially at the first DHR, were high dose drugs. In fact, we 
noticed that first DHR primarily occured with drugs used at daily doses above 1g. Especially 
betalactam antibiotics are often administered in doses well over 2g per day. Another observation 
is that a dose increase causes a delayed DHR (table 4, patient number 2). The doses for 
causative drugs in subsequent DHR were significantly lower (Fig. 2). An explanation might be, 
that T cells were already activated [11], and were able to react to lower doses. That could explain 
why in subsequent DHR a larger variety of drugs was able to react. 
c) The time interval between drug exposure and symptoms was substantially shorter in 
subsequent DHR. As already mentioned under point b, this would suggest that a lower 
cumulative drug dose is required to trigger further DHR.
d) Some drugs induced flare up reactions or a subsequent DHR. We assume that both 
phenomena are related. Drug induced flare up reactions have been observed in more than half of 
our patients (52.0%) of which 8 had DRESS and 2 a severe MPE. This suggests that drug 
induced flare up reactions may represent a milder/beginning DHR, whereby the immune stimulus 
is too weak to result in a permanent sensitization. Reoccurrence of cutaneous symptoms without 
sensitization as an aftereffect of a severe delayed DHR is not rare and -according to Picard - 
occurs in up to 25% [21]. Therefore, patients with drug induced flare-up reactions after a DHR 
may be at risk of developing MDH, when the exposure lasts longer. 
3. Tolerated drugs
For clinicians facing a patient with MDH it is important to offer a medication with a low probability 
to cause another DHR or flare-up reaction. In our MDH cohort macrolides, quinolones, 
doxycycline and linezolid have mostly been tolerated. Clindamycin on the other hand caused a 
subsequent DHR in 3 and a flare-up reaction in 2 subjects! Good tolerance was also seen to non-
aromatic antiepileptics, especially administered in low doses. Although severe DHR have been 
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Why some drugs cause DHR and others not, is unclear. Although the drug dose at subsequent 
DHR is lower, it might still be important. DHR to RCM, which are given only once, but in very high 
concentrations, indicate this. Two examples may illustrate the relevance of drug dose: We could 
observe a second DHR (DRESS) after increasing the dose of valproic acid (table 4, patient 
number 2). A second patient had several flare-up reactions, namely each time lamotrigine was 
increased to over 100mg (table 4, patient number 8). 
It is interesting to note that ibuprofen and paracetamol are often well tolerated. Although this 
contradicts our hypothesis about the influence of drug dose, many other factors, particularly 
metabolism, may play a role in terms of tolerability. In this respect it may be relevant that these 
drugs are frequently used only demand and not given continuously.
4. How can MDH courses be prevented concretely? 
A severe delayed DHR is a risk factor for subsequent DHR. This risk is highest in patients with 
DRESS (ca. 20%, own data). Therefore, a second DHR/MDH should be considered in every 
patient with DRESS or with severe exanthema, which do not fulfill the criteria for DRESS. Based 
on our experience, we propose the following approach in patients with severe delayed DHR or 
MDH: 
Use of low concentrations/drugs with high affinity for the original target: Since T cell mediated 
DHR are often off target activities on immune receptors, we would recommend drugs which have 
a high affinity for their target protein, and thus are effective in low concentrations (probably 2-digit 
mg range [7]). The concentration of such drugs may be too low for an off-target activity on 
immune receptors (pharmacological interaction of drugs with immune receptors), which seem to 
play a role in most of these T-cell reactions [12]. 
To avoid: Vancomycin and antibiotic sulfonamides should be avoided. Beta-lactam antibiotics 
should be administered when clearly indicated and introduced then likewise at the lowest 
effective dose. The same consideration applies for all new drugs, especially in patients with 
comorbidities such as renal insufficiency, autoimmune diseases or epilepsy. 
Probably allowed: Macrolides, quinolone antibiotics, doxycyclin and linezolid seem to be 
tolerated. Of the antiepileptic drugs, primarily non-aromatic variants and benzodiazepines should 
be chosen. The use of RCM and magnetic resonance contrast media needs to be limited. 
Metamizole and diclofenac should be avoided. Paracetamol and Ibuprofen seem to be a good 
alternative. Drugs to be avoided and often tolerated drugs in MDH are summarized in table 3.
This study is limited by the retrospective design. However, this was necessary to assess enough 
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study as a) we used quite stringent inclusion criteria; b) some patients with drug allergies to 
structurally unrelated drugs were probably not labeled as such and c) we assume that up to 25% 
of patients with DRESS develop a relapse [21]. The evaluation of drug dose is limited, as the 
number of cases is rather small and different drugs were compared. It must be taken into account 
that the drug dose at the subsequent DHR was influenced by the first DHR (increased use of 
reserve drugs). For further studies, our hypothesis of the relevance of the drug dose would have 
to be investigated within the same drug class and a higher number of study participants.
MDH is rare but for a patient with MDH a highly problematic iatrogenic disease.  Prospective 
multicenter studies on DRESS/MDH with clinical and laboratory analysis should be envisaged. 
Studies using T-cell phenotyping of DRESS patients with and without MDH should be performed 
and address the question why only a part of DRESS patients develop a MDH course. 
Conclusion
Our study describes clinical characteristics of patients with MDH with the aim to better understand 
how MDH progressions are favored. Patients with severe delayed DHR are at risk for MDH 
wherein betalactam antibiotics are often involved in inducing MDH. With regard to drugs, it seems 
advisable to avoid typical DRESS triggers, and to choose drugs which are effective in a low dose 
range. Some highly-dosed drugs as beta-lactam antibiotics, RCM and clindamycin should be 
avoided in further treatments, when alternatives are available. 
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Tables
Table 1 Inclusion criteria to diagnose multiple drug hypersensitivity syndrome.
Main criteria
Well documented drug hypersensitivity reaction: ≥1
Sensitization to ≥2 structurally different drug trigger in skin test
Sensitization to ≥2 structurally different drug trigger in cellular assay (ec. LTT)
Main criteria 1+2 or 1+3  should be fulfilled to diagnose MDH
Table 2 Patient characteristics
 MDH (total) MDH with single 
DHR
MDH with 2 or more 
DHR
    
 N=25 N=10 N=15
    
Demographics    
 Age at first reaction     50.0 (39.0; 65.0)       48.0 (35.5; 63.5)       60.0 (41.0; 65.0)   
 Gender (female)       15 (60.0%)           5 (60.0%)           10 (60.0%)     
Preexisting conditions    
 Atopic disposition       4 (16.0%)           1 (10.0%)           3 (20.0%)     
 Epilepsy       8 (32.0%)           3 (30.0%)           5 (33.3%)     
 Autoimmune disorder       7 (28.0%)           2 (20.0%)           5 (33.3%)     
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Type of first DHR    
 IgE mediated (anaphylaxis)  1 (4.0%)  -  1 (6.7%)
 DRESS  14 (56.0%)  6 (60.0%)  8 (53.3%)
 MPE  5 (25.0%)  2 (20.0%)  3 (20.0%)
 SJS / TEN  2 (8.0%)  1 (10.0%)  1 (6.7%)
 AGEP  2 (8.0%)  1 (10.0%)  1 (6.7%)
 Bullous exanthema  1 (4.0%)  -  1 (6.7%)
Drug induced flare-up reactions  13 (52.0%)  3 (30.0%)  10 (66.7%)
Type of MDH recurrence    
 DRESS  -  -  2 (13.3%)
 MPE  -  -  11 (73.3%)
 SDRIFE  -  -  1 (6.7%)
 AGEP  -  -  3 (20.0%)
Months to second DHR  -  -  26 (6.0; 71.0)
Type of MDH    
 simultaneous  5 (20.0%)  5 (50.0%)  -
 sequential  6 (24.0%)  4 (40.0%)  2 (56.0%)
 distant  11 (44.0%)  -  11 (25.0%)
 overlap  3 (12.0%)  1 (10.0%)  2 (8.0%)
In MDH with single DHR, drug trigger were given in combination therapies or sequentially within the same 
drug hypersensitivity (DHR) episode. Values are median and interquartile ranges (IQR) for continuous 
variables. Categorical variables reported as n (%).  
Multiple drug hypersensitivity syndrome (MDH), drug reaction with eosinophilia and systemic symptoms 
(DRESS), maculopapular exanthema (MPE), anaphylaxis (ANA), acute generalized exanthematous 
pustulosis (AGEP), symmetrical drug related flexural and intertriginous exanthema (SDRIFE), stevens 
johnson syndrome (SJS), toxic epidermal necrolysis (TEN)
Figure 1
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All values are reported as n. Multiple drug hypersensitivity syndrome (MDH), drug hypersensitivity reaction 
(DHR), antiepileptic drugs (AED), radio contrast media (RCM), proton pump inhibitors (PPI).
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Figure 2
Comparison of daily doses of drug trigger (2a) and latency period (2b) in MDH patients with delayed drug 
hypersensitivity reactions (DHR) (n=24)
Figure 2a
Daily doses (mg) of MDH trigger between the first (A: 1875.0 mg (662.5; 2100.0)) and subsequent DHR (B: 
600.0 mg (300.0; 1300.0)) were compared, using the Man-Whitney U test (p=0.0420). Values are median 
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The latency period between the first (A: 19.0 days (9.0; 28.0)) and subsequent DHR was compared (B: 3.0 
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Table 3 
List of drugs that can promote subsequent DHR or drug induced flare-up reactions in MDH and drugs which 
were mostly tolerated in subsequent pharmacological treatments.
Drugs often involved in subsequent reactions Drugs, which are mostly well tolerated
Antibiotics
Penicillins (esp. Piperacillin, Amoxicillin) (4/6) Macrolides (2/2)
Cephalosporins (esp. Cefuroxim, Ceftriaxon, 
Cefepime) (4/12) Quinolones (7/9)
Vancomycin (0/2) Linezolid (2/2)





Non aromatic anticonvulsants (esp. levetiracetam, 
valproic acid, topiramat) (8/10)
Benzodiazepines (4/4)
Analgesics
Metamizole (4/7) Paracetamol (11/12)




All radio contrast media (2/5)
† Lamotrigin over 100mg daily dose
The values indicate the relationship of patients who were exposed to a particular drug after the first DHR 
and how many of them tolerated it (tolerated/exposed). Drugs were classified as mostly tolerable, if 
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Table 4
Characteristics of the MDH hypersensitivity reactions and allergy workup in 25 participating subjects
Patient
Type of initial 









up reaction (no 
sensitization)
Tolerated drugs after first 
DHR























3 DRESS Sulfamethoxazol PT + + DRESS Vancomycin PT + + Ceftriaxon










































+ MPE Iobitridol PT + + Clindamycin
Aspirin, paracetamol, 
cefuroxim







































11 AGEP Hydoxychloroquin n/a + MPE Budesonid PT + n/a Aspirin, levetiracetam
































PT +, IDT +
PT +, IDT +





+ n/a n/a n/a n/a No data












- Diclofenac, valproic acid







+ n/a n/a n/a  n/a  No data
17 Severe MPE Flucloxacillin PT + - MPE Norfloxacin PT + + Cefepime No drugs









































































Patch test (PT), intradermal test (IDT), lymphocyte transformation test (LTT), drug provocation test (DPT), drug reaction with eosinophilia and systemic symptoms 
(DRESS), maculopapular exanthema (MPE), anaphylaxis (ANA), acute generalized exanthematous pustulosis (AGEP), symmetrical drug related flexural and 
intertriginous exanthema (SDRIFE), stevens johnson syndrome (SJS), toxic epidermal necrolysis (TEN), not applicable (n/a) 
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